Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00653068 · OUTCOME

Event-free Survival

Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System · Source last updated 2024-04-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Estimated probability
Interval / dispersion
95% Confidence Interval
Time frame
Up to 4 years after study enrollment

What was measured

Estimated 4-year EFS where EFS is calculated as the time from study enrollment to disease progression, disease relapse, occurrence of a second malignant neoplasm, death from any cause or last follow-up whichever occurs first. Kaplan-Meier method is used for estimation. Patients without an event are censored at last contact.

Analysis population: One patient was ineligible in stratum I and one patient was ineligible in stratum III. There were no patients enrolled in Stratum 2 or 4.

Groups in this outcome

Stratum I

Infants (\<36 months of age) with tumor histology and immunohistochemical analysis diagnostic of AT/RT.

Stratum III

Older children (greater than 36 months of age) with tumor histology and immunohistochemical analysis diagnostic of AT/RT.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Stratum I57
Stratum III11

Reported measurements

Source class 1
Values in Estimated probability · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Stratum I0.3401Not reported0.21740.4666Not reported
Stratum III0.4500Not reported0.12670.7345Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.2174
        upper Limit
        0.4666
        value
        0.3401
      2. group Id
        OG001
        lower Limit
        0.1267
        upper Limit
        0.7345
        value
        0.4500
denoms
  1. counts
    1. group Id
      OG000
      value
      57
    2. group Id
      OG001
      value
      11
    units
    Participants
description
Estimated 4-year EFS where EFS is calculated as the time from study enrollment to disease progression, disease relapse, occurrence of a second malignant neoplasm, death from any cause or last follow-up whichever occurs first. Kaplan-Meier method is used for estimation. Patients without an event are censored at last contact.
dispersion Type
95% Confidence Interval
groups
  1. description
    Infants (\<36 months of age) with tumor histology and immunohistochemical analysis diagnostic of AT/RT.
    id
    OG000
    title
    Stratum I
  2. description
    Older children (greater than 36 months of age) with tumor histology and immunohistochemical analysis diagnostic of AT/RT.
    id
    OG001
    title
    Stratum III
param Type
NUMBER
population Description
One patient was ineligible in stratum I and one patient was ineligible in stratum III. There were no patients enrolled in Stratum 2 or 4.
reporting Status
POSTED
time Frame
Up to 4 years after study enrollment
title
Event-free Survival
type
PRIMARY
unit Of Measure
Estimated probability

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice